Jonathan Aschoff
Stock Analyst at Roth MKM
(0.55)
# 3,771
Out of 4,814 analysts
43
Total ratings
21.15%
Success rate
-35.89%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GTBP GT Biopharma | Initiates: Buy | $11 | $2.20 | +400.00% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $7.16 | +193.30% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $555 → $296 | $0.86 | +34,242.73% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.75 | +928.51% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $17 | $0.93 | +1,719.15% | 2 | Aug 13, 2024 | |
| OTRK Ontrak | Maintains: Buy | $60 → $45 | $1.41 | +3,091.49% | 2 | Aug 9, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $0.84 | +2,273.04% | 1 | Jul 16, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Maintains: Buy | $21 → $11 | $0.23 | +4,765.10% | 2 | May 3, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $40 | $0.86 | +4,551.16% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $20 → $28 | $0.30 | +9,391.53% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $36 | $5.77 | +523.92% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $24 | $0.28 | +8,474.49% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $5.20 | +476.92% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $3.00 | +6,566.67% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $1.62 | +764.20% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2,400 → $7,200 | $3.08 | +233,666.23% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $0.65 | +1,124.74% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $1.95 | +5,028.21% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.80 | +49,900.00% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $3.38 | +1,024.26% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24,000 | $0.81 | +2,959,209.49% | 1 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $1.74 | +5,417.24% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $7.35 | +76.87% | 1 | Dec 19, 2019 |
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $2.20
Upside: +400.00%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $7.16
Upside: +193.30%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $555 → $296
Current: $0.86
Upside: +34,242.73%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.75
Upside: +928.51%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $17
Current: $0.93
Upside: +1,719.15%
Ontrak
Aug 9, 2024
Maintains: Buy
Price Target: $60 → $45
Current: $1.41
Upside: +3,091.49%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $0.84
Upside: +2,273.04%
Cyclacel Pharmaceuticals
May 3, 2024
Maintains: Buy
Price Target: $21 → $11
Current: $0.23
Upside: +4,765.10%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $0.86
Upside: +4,551.16%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $20 → $28
Current: $0.30
Upside: +9,391.53%
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $5.77
Upside: +523.92%
Mar 5, 2024
Maintains: Buy
Price Target: $5 → $24
Current: $0.28
Upside: +8,474.49%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $5.20
Upside: +476.92%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $3.00
Upside: +6,566.67%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $1.62
Upside: +764.20%
Feb 14, 2023
Maintains: Buy
Price Target: $2,400 → $7,200
Current: $3.08
Upside: +233,666.23%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $0.65
Upside: +1,124.74%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $1.95
Upside: +5,028.21%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.80
Upside: +49,900.00%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $3.38
Upside: +1,024.26%
Feb 12, 2021
Initiates: Buy
Price Target: $24,000
Current: $0.81
Upside: +2,959,209.49%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $1.74
Upside: +5,417.24%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $7.35
Upside: +76.87%